KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation & Amortization (CF) (2016 - 2025)

CRISPR Therapeutics AG's Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $5.7 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 16.91% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $19.5 million, up 1.14%, while the annual FY2025 figure was $19.5 million, 1.14% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $5.7 million at CRISPR Therapeutics AG, up from $4.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $7.3 million in Q2 2022 and bottomed at $2.7 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $4.9 million (2023), against an average of $5.0 million.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 144.0% in 2021 before it crashed 31.75% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $6.3 million in 2021, then fell by 6.63% to $5.8 million in 2022, then fell by 16.18% to $4.9 million in 2023, then dropped by 1.18% to $4.8 million in 2024, then grew by 16.91% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Depreciation & Amortization (CF) are $5.7 million (Q4 2025), $4.4 million (Q3 2025), and $4.6 million (Q2 2025).